This webinar focuses on the clinical trial data for Biogen’s investigational drug aducanumab. If approved, aducanumab would be the first disease-modifying treatment for Alzheimer’s disease.
There are over 50 million people with dementia worldwide as of 2020. An increasing proportion live in low and middle income countries. These estimates are based on the best currently available evidence as explained here.
Our infographic showing 12 modifiable risk factors for dementia.
This webinar featured a panel discussion with experts from around the world who presented on the areas of dementia risk reduction, NCDs, air pollution, and the lived experience of dementia during COVID-19.
This webinar focuses on key issues emerging around dementia care and palliative care during the COVID-19 pandemic, and crucially how these can be taken forward.
The third Dementia Innovation Readiness Index focuses on city-level innovation readiness to dementia in 30 major cities globally.
Find information about Alzheimer's disease and other dementias in languages other than English
The World Alzheimer Report 2020 gives a global perspective of dementia-related design that takes a cross cultural approach and spans across two volumes, including 84 case studies and interviews with leaders in the field of dementia design.